1. Show article details.

    Vaxart To Present at Upcoming Vaccine Conferences

    PR Newswire – 4:05 PM ET 09/22/2021

    SOUTH SAN FRANCISCO, Calif. ID Week 2021: September 29, 2021 – October 3, 2021 ID Week is the joint annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.

  2. Show article details.

    Vaxart Announces Creation of Manufacturing and Quality Advisory Board

    PR Newswire – 4:15 PM ET 09/21/2021

    SOUTH SAN FRANCISCO, Calif.

  3. Show article details.

    BRIEF-Vaxart May Offer And Sell Shares With Aggregate Offering Price Of Up To $100 Mln

    Reuters – 6:10 AM ET 09/16/2021

    Vaxart Inc (VXRT): * Vaxart Inc (VXRT) - MAY OFFER AND SELL SHARES HAVING AN AGGREGATE OFFERING PRICE OF UP TO $100.0 MILLION. * Vaxart Inc (VXRT) - TERMINATED THE OPEN MARKET SALE AGREEMENT DATED OCTOBER 14, 2020 Source text for Eikon: [https://bit.ly/3Elyfu5] Further company coverage:

  4. Show article details.

    Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    PR Newswire – 4:20 PM ET 09/07/2021

    SOUTH SAN FRANCISCO, Calif. Monday, Sept. 13, 2021, and on Vaxart's (VXRT) website. Vaxart's (VXRT) oral tablet COVID-19 vaccine is "The Pill that Moves the Needle" and the only oral COVID-19 vaccine whose potential is backed by clinical data. About VaxartVaxart (VXRT) is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.

  5. Show article details.

    BRIEF-Vaxart Announces Julie M. Cherrington Joins Board Of Directors

    Reuters – 9:11 AM ET 08/23/2021

    Vaxart Inc (VXRT): * VAXART ANNOUNCES HIGHLY REGARDED BIOTECH EXECUTIVE JULIE M. CHERRINGTON, PH.D., JOINS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

  6. Show article details.

    Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors

    PR Newswire – 9:00 AM ET 08/23/2021

    SOUTH SAN FRANCISCO, Calif. Julie Cherrington to the Vaxart Board of Directors," said Vaxart Board Chairman Todd C. Davis. "She has had a high-caliber career in life sciences and is the leader of a cutting-edge clinical stage biotech company.

  7. Show article details.

    Vaxart Announces Creation of New Scientific and Clinical Advisory Board

    PR Newswire – 4:02 PM ET 08/19/2021

    SOUTH SAN FRANCISCO, Calif. July 24, 2021, is comprised of medical and health care professionals who are vaccine, research, and academic experts in immunology, microbiology, and infectious diseases.  . "We are excited to have such preeminent leaders in their fields joining our Scientific and Clinical Advisory Board," said Andrei Floroiu, Vaxart's Chief Executive Officer.

  8. Show article details.

    Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results

    PR Newswire – 4:02 PM ET 08/05/2021

    SOUTH SAN FRANCISCO, Calif. June 30, 2021. "By any measure, Vaxart (VXRT) showed real forward momentum during the last quarter," CEO Andrei Floroiu said.

  9. Show article details.

    BRIEF-Vaxart Inc Estimates Its Cash And Cash Equivalents As Of June 30, 2021, Was About $198.9 Million

    Reuters – 5:20 PM ET 08/02/2021

    Vaxart Inc (VXRT): * Vaxart Inc (VXRT) - ESTIMATES ITS CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2021, WAS ABOUT $198.9 MILLION Source text Further company coverage:

  10. Show article details.

    BRIEF-FDA Clears Vaxart's IND Application For S-Only Oral Tablet Covid-19 Vaccine Candidate

    Reuters – 8:03 AM ET 08/02/2021

    Vaxart Inc (VXRT): * FDA CLEARS VAXART'S IND APPLICATION FOR S-ONLY ORAL TABLET COVID-19 VACCINE CANDIDATE. * Vaxart Inc (VXRT) - PHASE II CLINICAL TRIAL WITH S-ONLY CONSTRUCT IS EXPECTED TO START IN 2H21 Source text for Eikon: Further company coverage:

  11. Show article details.

    FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

    PR Newswire – 8:00 AM ET 08/02/2021

    SOUTH SAN FRANCISCO, Calif. Andrei Floroiu, Vaxart's Chief Executive Officer. "Together, the S-only and S+N constructs are part of our unique oral tablet COVID-19 vaccine candidate portfolio, which we believe could make a significant contribution to the fight against COVID-19 globally."

  12. Show article details.

    BRIEF-Vaxart Reports Boosting Immune Responses In Subjects Previously Vaccinated By A Vaxart Vaccine

    Reuters – 12:28 PM ET 07/29/2021

    Vaxart Inc (VXRT): * VAXART REPORTS BOOSTING IMMUNE RESPONSES IN SUBJECTS PREVIOUSLY VACCINATED BY A VAXART VACCINE. * Vaxart Inc (VXRT) - FIRST BOOSTER CLINICAL STUDY BY VAXART SHOWS BOOSTED IMMUNE RESPONSES SIMILAR TO ORIGINAL RESPONSES WITH VAXART VACCINE. * Vaxart Inc (VXRT) - FINDINGS HAVE POTENTIAL IMPLICATIONS FOR VAXART'S COVID-19 ORAL VACCINE PROGRAM Source text for Eikon: Further company coverage:

  13. Show article details.

    Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

    PR Newswire – 8:22 AM ET 07/29/2021

    SOUTH SAN FRANCISCO, Calif. Andrei Floroiu, Vaxart's Chief Executive Officer. "We are excited by these findings and by the implications for all of our vaccines." "Using our oral norovirus vaccine candidate, we successfully boosted the immune responses of those previously vaccinated with our platform," said Dr. Sean Tucker, Vaxart's (VXRT) founder and Chief Scientific Officer.

  14. Show article details.

    BRIEF-Vaxart Announces Exclusive Worldwide License Agreement With Altesa Biosciences For Its Vapendavir Antiviral Asset

    Reuters – 8:23 AM ET 07/07/2021

    Vaxart Inc (VXRT): * VAXART ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH ALTESA BIOSCIENCES FOR ITS VAPENDAVIR ANTIVIRAL ASSET. * Vaxart Inc (VXRT) - MILESTONE PAYMENTS UP TO $130 MILLION AND ROYALTIES FOR GLOBAL VAPENDAVIR SALES.

  15. Show article details.

    Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

    GlobeNewswire – 8:00 AM ET 07/07/2021

    Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demonstrated activity against a broad spectrum of enteroviruses.

  16. Show article details.

    Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

    GlobeNewswire – 9:00 AM ET 06/07/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time.

  17. Show article details.

    Vaxart to Present at the Jefferies Virtual Healthcare Conference

    GlobeNewswire – 8:00 AM ET 05/27/2021

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu, CEO and Sean Tucker, CSO of the Vaxart (VXRT) executive team are scheduled to present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 p.m. Eastern Time.

  18. Show article details.

    Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

    GlobeNewswire – 8:00 AM ET 05/07/2021

    Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine. Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population.

  19. Show article details.

    Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

    GlobeNewswire – 8:00 AM ET 05/04/2021

    Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year. Study results may inform the COVID-19 oral vaccine program.

  20. Show article details.

    New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

    GlobeNewswire – 5:06 PM ET 05/03/2021

    Vaxart (VXRT) oral vaccine induced higher CD8+ T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa, show broad cross-reactivity SOUTH SAN FRANCISCO, Calif., May 03, 2021 -- Vaxart (VXRT), Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rathe...

Page:

Today's and Upcoming Events

  • Nov
    10

    VXRT to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    05

    VXRT announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.